HKELECTRIC-SS(02638) released its 2025 annual performance, with a net profit attributable to shareholders of HK$3.149 billion, representing a year-on-year growth of 1.2%.
Hong Kong Electric Holdings Limited (02638) announced its full-year results for 2025, with revenue of HK$12.125 billion, an increase of 0.6% year-on-year. The attributable surplus to shareholders of the Company amounted to HK$3.149 billion, an increase of 1.2% year-on-year, with earnings per share of HK$0.3564.
HKELECTRIC-SS (02638) announced its full-year performance for 2025, with a revenue of HK$12.125 billion, a year-on-year growth of 0.6%; the attributable net profit to shareholders was HK$3.149 billion, a year-on-year increase of 1.2%; and the earnings per share were 35.64 HK cents.
During the year, HK Electric continued to advance various major projects under the 2024-2028 development plan, in line with the carbon reduction goals of the Hong Kong SAR government. The construction of the new gas combined cycle power unit L13, as well as three new single-cycle fuel oil units, progressed smoothly. These projects will help improve power generation safety, ensure system reliability, and further reduce carbon emissions. The company has also nearly completed the installation of smart meters for all customers.
Looking ahead, affordable electricity prices remain a significant concern for customers. HK Electric will reduce the net electricity tariff by 2.2% to HK$0.1633 per kWh in January 2026, mainly due to a decrease in fuel adjustment charges. Despite the need for an increase in the basic electricity tariff due to continued capital investments, the net electricity tariff has seen a decrease. The company is committed to managing electricity prices to strike a balance between affordability, reliability of supply, and long-term sustainable development.
Related Articles

CENTURY EN INTL(08132): Su Ya appointed as the new auditor

SIMCERE PHARMA(02096): SIM0237 clinical study data for non-muscle invasive bladder cancer stages I/II will be released at the 2026 European Society of Urology annual meeting.

CK Life Sciences (00775) announces its annual performance, with a net loss attributable to shareholders of HK$187 million, representing an increase of 47.61% year-on-year.
CENTURY EN INTL(08132): Su Ya appointed as the new auditor

SIMCERE PHARMA(02096): SIM0237 clinical study data for non-muscle invasive bladder cancer stages I/II will be released at the 2026 European Society of Urology annual meeting.

CK Life Sciences (00775) announces its annual performance, with a net loss attributable to shareholders of HK$187 million, representing an increase of 47.61% year-on-year.

RECOMMEND

European Carmakers Embrace China: Under Technology And Cost Pressure, Stellantis And Mercedes Seek Partnerships With Chinese Automakers
17/03/2026

HKEX Listing Mechanism Reform Revisited: How To Balance New Favorites And Established Names
17/03/2026

International Oil Prices Plunge Boosts U.S. Stocks; Morgan Stanley Chief Says Market Correction Nearing End
17/03/2026


